Adjusted daily closes · 252 observations · as of Nov 6, 2026
Historical data, not a forecast
1 month
+18.8%
3 months
+8.3%
6 months
+28.9%
1 year
+20.6%
Year to date
+18.4%
52-week range
$79.16 – $110.15
Fundamental snapshot
Latest reported period: Sep 30, 2026
Sharadar reported data
Market cap
$19.98B
P/E
26
P/B
1.6
P/S
2.3
Revenue
$8.57B
Net income
$767.3M
Diluted EPS
3.96
Gross margin
69.70%
Net margin
9.00%
Return on equity
6.10%
Total debt
$7.5B
Cash
$399.9M
Free cash flow
$1.29B
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Sep 30, 2026
$2.06B
$191.6M
71.20%
9.30%
$372.4M
Jun 30, 2026
$2.18B
$198.3M
70.80%
9.10%
$308.2M
Mar 31, 2026
$2.09B
$238.1M
72.40%
11.40%
$245.9M
Dec 31, 2025
$2.24B
$139.3M
64.70%
6.20%
$368.3M
Sep 30, 2025
$2B
$230.9M
72.10%
11.50%
$277.7M
Jun 30, 2025
$2.08B
$152.8M
71.50%
7.40%
$247.6M
Mar 31, 2025
$1.91B
$182M
71.20%
9.50%
$278.5M
Dec 31, 2024
$2.02B
$239.5M
71.00%
11.80%
-$1.1B
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Shoulder Innovations reported a significant 38% year-over-year increase in net revenue to $16.2 million for Q3FY26, driven by a 34% rise in implant volumes and higher average selling prices. The company also improved its gross margin to 78.5% and narrowed its net loss, leading to a raised full-year FY26 revenue guidance of $68-$70 million. Strategic product launches and advancements in its robotics platform are key to its continued growth and long-term margin expansion.
Shoulder Innovations (SI) reported a 37.7% increase in third-quarter revenue to $16.191 million, up from $11.756 million a year earlier, with gross margin improving to 78.5% from 76.2%. Despite narrowing its net loss to $7.048 million from $8.729 million, the company saw its nine-month operating loss widen to $26.609 million due to increased operating expenses. SI is focusing on continued growth through product development, expansion into outpatient settings, and strategic investments in its ecosystem, including a new robotics platform.
Zimmer Biomet reported strong third-quarter 2026 results, with net sales exceeding expectations and a 3.7% constant currency growth. The company raised its full-year organic constant currency sales growth guidance to 3.0%-3.5% and adjusted EPS to $8.50-$8.60, marking the second raise this year. CEO Ivan Tornos highlighted the accelerated timeline for the Monogram robotic system's FDA submission and anticipated launch of a fully autonomous version in 1H 2027, ahead of schedule, projecting 2027 to be a better year for the company.